Dose escalation of CPI-613 with bendamustine for relapsed T Cell NHL

Bookmark and Share
Published: 6 Dec 2016
Views: 2255
Dr Zanetta Lamar - Wake Forest Baptist Medical Center, Winston-Salem, USA

Dr Lamar speaks with ecancertv at ASH 2016 about phase I dose escalation of CPI-613, a metabolic inhibitor, in combination with bendamustine.

She summarises the incidence and outlook of refractory T cell non-Hodgkin lymphoma (NHL), and the escalation of a small patient subgroup from 2000mg/m2, limited by toxicity.

The overall response rate was 80%, and Dr Lamar describes these initial results as signs of an important crack in the armour of T cell lymphoma.

CPI-613 was discussed further by Dr Tim Pardee here.

ecancer's filming at ASH 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.